©2024 Stanford Medicine
Feasibility of Telehealth Palliative Care and Digital Symptom Monitoring for Patients With Acute Myeloid Leukemia
Recruiting
I'm InterestedTrial ID: NCT04885127
Purpose
AML is the most common leukemia diagnosed in adults. In spite of recent low-intensity
therapies that have improved outcomes for older AML patients, AML remains associated with
poor prognosis as well as high symptom burden. While the benefits of early palliative care as
well as electronic PROs have been well-described in the oncology population, neither have
been well-studied in the AML population, and have never been studied in combination. We
propose a prospective, single-center, single-arm trial to evaluate the feasibility of a
virtually-mediated supportive care model utilizing both electronic PROs and palliative care
for patients with AML being treated with low-intensity therapy.
AIM1: is to evaluate and describe the feasibility of implementing early specialty palliative
care referrals carried out via telehealth/video-based modalities in combination with digital
symptom monitoring for patients recently diagnosed with acute myeloid leukemia (AML) and
starting low intensity induction therapy.
AIM2: study the differences in health-related quality-of-life (HRQoL) metrics using
patient-reported outcomes (PROs) in patients recently diagnosed with AML and starting low
intensity induction therapy who receive early referral to telehealth/video-based palliative
care visits compared to standard care.
AIM3: to explore the patient experience of patients with AML on low-intensity therapy,
capture rates of advance care planning, hospice utilization, and hospital utilization.
Official Title
The Feasibility of Telehealth-Based Palliative Care Intervention and Digital Symptom Monitoring on Patients With AML Receiving Low-Intensity Induction Therapy
Stanford Investigator(s)
Gabriel Mannis
Associate Professor of Medicine (Hematology)
Kavitha Ramchandran
Clinical Professor, Medicine - Oncology
Eligibility
Inclusion Criteria:
- Patients being treated for a diagnosis of acute myeloid leukemia at Stanford Cancer
Center
- Patients determined to be candidates for low intensity induction therapy (not
requiring hospitalization to administer treatment) by their leukemia physician
- Estimated life expectancy of 6 months
- Functional status at the level of at least being capable of limited self-care,
confined to chair or bed for half the day or better
- Access to smartphone, tablet, or computer with capability to utilize a symptom
tracking application
Exclusion Criteria:
- Relapsed or refractory AML
- Patients who have established care with palliative care previously
- Non-English-speaking, as the Noona application is developed in the English language
Intervention(s):
other: Palliative Care + Digital Symptom Monitoring
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Irena Tan, MD